×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RLMD – relmada therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
07:30 am
rlmd
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Low
Report
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
11/19
09:06 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
11/13
04:20 pm
rlmd
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Medium
Report
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
11/7
07:30 am
rlmd
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Low
Report
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
11/4
07:09 am
rlmd
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
High
Report
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
11/4
07:01 am
rlmd
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
High
Report
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
10/31
01:05 pm
rlmd
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/7
07:48 am
rlmd
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
04:01 pm
RLMD
relmada therapeutics, inc.
MISS
Report
-0.5%
relmada therapeutics, inc.
8/7/2025
04:05 pm
RLMD
relmada therapeutics, inc.
MISS
Report
-2.4%
relmada therapeutics, inc.
5/12/2025
04:01 pm
RLMD
relmada therapeutics, inc.
MISS
Report
-2.1%
relmada therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:28 pm
rlmd
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Ikarian Capital, LLC
Medium
Report
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Ikarian Capital, LLC
11/6
07:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Shenouda Maged
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Shenouda Maged
11/6
07:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Ence Chuck
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Ence Chuck
11/6
07:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: TRAVERSA SERGIO
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: TRAVERSA SERGIO
11/6
07:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Kelly Paul Edward
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Kelly Paul Edward
11/5
06:05 am
rlmd
Form 8-K RELMADA THERAPEUTICS, For: Nov 04
Low
Report
Form 8-K RELMADA THERAPEUTICS, For: Nov 04
11/5
06:05 am
rlmd
Form 424B5 RELMADA THERAPEUTICS,
Low
Report
Form 424B5 RELMADA THERAPEUTICS,
11/4
08:30 am
rlmd
Form FWP RELMADA THERAPEUTICS, Filed by: RELMADA THERAPEUTICS, INC.
High
Report
Form FWP RELMADA THERAPEUTICS, Filed by: RELMADA THERAPEUTICS, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
TOP News Decliners
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: